Acute Pulmonary Edema

🩺What is Acute Pulmonary Edema?

The Killip classification was introduced by Thomas Killip III and John T. Kimball in 1967 in a landmark article published in the American Journal of Cardiology describing their two-year experience treating 250 patients with acute myocardial infarction in a dedicated coronary care unit at the New York Hospital-Cornell Medical Center. The classification is a bedside clinical tool that stratifies patients with acute MI by the severity of heart failure based solely on physical examination findings: auscultation for rules (crepitations) and the presence of an S3 gallop rhythm, inspection for elevated jugular venous pressure, and assessment of blood pressure and peripheral perfusion. The original study demonstrated a dramatic stepwise increase in in-hospital mortality: Class I (no heart failure) 6% mortality, Class II (mild to moderate heart failure with rales and S3) 17% mortality, Class III (severe heart failure with acute pulmonary edema) 38% mortality, and Class IV (cardiogenic shock) 81% mortality. Despite being over five decades old, the Killip classification has been validated in hundreds of thousands of patients across multiple continents and treatment eras — the pre-thrombolytic era, the thrombolytic era, and the contemporary primary percutaneous coronary intervention (PCI) era. A 2016 meta-analysis of 18 studies involving over 350,000 patients confirmed that Killip class remains one of the strongest independent predictors of short-term mortality after adjustment for age, sex, comorbidities, infarct location, and reperfusion strategy. In the contemporary PCI era, the mortality rates have improved compared to the original 1967 report but the stepwise relationship persists: Class I approximately 2-4%, Class II approximately 8-12%, Class III approximately 20-30%, and Class IV approximately 40-60%. The classification is universally recognized by cardiology societies worldwide, including the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation. It is incorporated into all major acute coronary syndrome guidelines and is a required data element in all contemporary MI registries such as the National Cardiovascular Data Registry (NCDR) CathPCI Registry, the GRACE registry, and the Swedish SWEDEHEART registry. The Killip classification's enduring value lies in its remarkable simplicity — it requires no equipment beyond a stethoscope and a blood pressure cuff — yet provides prognostic discrimination comparable to complex multivariable risk scores.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Acute Pulmonary Edema:

• Killip Class Calculator — Heart Failure in Myocardial Infarction

  The Killip classification is a simple clinical tool used to classify the severity of heart failure in patients presenting with acute myocardial infarction, providing prognostic information on in-hospital mortality.

🧬Diagnostic Logic & Scoring Breakdown

The Killip class is not a calculated score with weighted variables but a clinical classification assigned based on the most severe heart failure finding on physical examination. The classification proceeds in four ordered categories. Class I (No Heart Failure): the patient has no clinical signs of heart failure. No rales (crepitations) are heard on lung auscultation, no S3 gallop is present, jugular venous pressure is not elevated, and there are no signs of peripheral hypoperfusion. These patients represent approximately 50-60% of acute MI presentations. Class II (Mild to Moderate Heart Failure): the patient has clinical evidence of heart failure characterized by an S3 gallop rhythm (a low-frequency ventricular filling sound best heard at the apex), rales or crepitations covering less than 50% of the lung fields (usually bibasilar), and elevated jugular venous pressure. These findings indicate pulmonary venous hypertension secondary to left ventricular diastolic dysfunction with preserved systolic function or mild systolic dysfunction. Approximately 20-30% of MI patients present as Killip Class II. Class III (Severe Heart Failure / Acute Pulmonary Edema): the patient has frank acute pulmonary edema with rales or crepitations covering more than 50% of the lung fields, often extending to the upper lung zones. These patients are in severe respiratory distress with orthopnea, hypoxia (O2 saturation <90%), and require immediate respiratory support. This category represents approximately 10-15% of acute MI presentations. Class IV (Cardiogenic Shock): the patient has cardiogenic shock defined as systolic blood pressure <90 mmHg (or requiring vasopressors to maintain SBP >90) combined with signs of end-organ hypoperfusion: oliguria (urine output <30 mL/hour), cold and clammy extremities, altered mental status (confusion or lethargy), and metabolic acidosis. Despite representing only 5-10% of acute MI presentations, these patients have the highest mortality. The in-hospital mortality increases stepwise: Class I approximately 2-6% depending on the era and treatment received, Class II approximately 10-17%, Class III approximately 25-38%, and Class IV approximately 50-67%. The Killip class should be reassessed throughout hospitalization because patients may improve with revascularization and medical therapy (e.g., from Class III to Class II), or deteriorate (e.g., from Class II to Class IV in the setting of mechanical complications such as papillary muscle rupture or ventricular septal defect).

📢Clinical Significance & Implications

The Killip classification is one of the most important risk stratification tools in acute coronary syndrome care, and its use is recommended by all major cardiology guidelines including the 2024 AHA/ACC Guideline for the Management of Patients With Acute Coronary Syndromes, the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes, and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. The classification provides critical prognostic information that directly influences triage decisions and intensity of care. In clinical practice, Killip class is used to: (1) determine the level of care required — Class I and selected Class II patients can be managed on telemetry or step-down units, while Class III and IV patients require intensive care unit admission; (2) guide the timing and strategy of revascularization — Class I and II patients should undergo early invasive strategy within 24 hours, while Class III and IV patients often require urgent or emergency revascularization with hemodynamic support; (3) identify patients who need mechanical circulatory support — Class IV patients may benefit from intra-aortic balloon pump, Impella, or venoarterial extracorporeal membrane oxygenation pending recovery or as a bridge to advanced therapies; (4) determine the appropriateness of beta-blocker initiation — beta-blockers should be used cautiously in Class III and IV patients due to the risk of worsening hemodynamics. The Killip class is also a critical component of other risk stratification scores. The TIMI risk score for STEMI includes Killip class as one of its strongest predictors (each Killip class increment is assigned incremental points), and the GRACE risk score incorporates Killip class equivalent parameters such as heart failure and shock. Beyond acute management, Killip class predicts longer-term outcomes including 6-month and 1-year mortality, heart failure hospitalization, and sudden cardiac death. Several studies have also demonstrated that Killip class predicts the risk of ventricular arrhythmias during hospitalization, with Class III and IV patients having a 3-5 fold higher risk of sustained ventricular tachycardia or ventricular fibrillation. In contemporary practice, the Killip class is recorded for every MI patient in cardiovascular registries and it remains a mandatory data element for clinical trial stratification, ensuring comparability across study populations.

💡 Clinical Assessment Scenario Example

A 65-year-old man with a history of hypertension, type 2 diabetes, and prior inferior MI (stented 3 years ago) presents to the emergency department with severe central chest pain of 2 hours duration, radiating to the left arm and jaw. He is diaphoretic, nauseated, and reports severe shortness of breath. Vital signs: blood pressure 85/50 mmHg (right arm, supine), heart rate 110 bpm (sinus tachycardia), respiratory rate 28 breaths per minute, oxygen saturation 88% on room air (improves to 93% on 10 L non-rebreather mask), temperature 36.8°C. Physical examination: awake but confused and agitated. Jugular venous pressure is elevated at 12 cm H2O. Lung auscultation reveals bilateral coarse rales (crepitations) extending to the upper third of both lung fields, consistent with acute pulmonary edema (rales >50%). Cardiac auscultation reveals a soft S1, a prominent S3 gallop at the apex, and no murmurs. Extremities are cold, clammy, and mottled; capillary refill time is 5 seconds. Urine output over the past hour is 15 mL (oliguric). ECG shows ST-segment elevation of 4 mm in leads V1-V6 with reciprocal ST depression in leads II, III, and aVF, consistent with acute extensive anterior STEMI. Chest X-ray shows pulmonary edema with cephalization of pulmonary vessels and bilateral fluffy opacities. Initial laboratory studies: troponin I >50 ng/mL, creatinine 1.3 mg/dL (baseline 1.0), lactate 4.2 mmol/L, arterial blood gas pH 7.29 with metabolic acidosis. Killip classification: the patient has cardiogenic shock criteria — systolic BP <90 mmHg, evidence of pulmonary edema (rales >50%), and end-organ hypoperfusion (altered mental status, oliguria, cold extremities, metabolic acidosis). Killip Class IV (Cardiogenic Shock) with predicted in-hospital mortality of approximately 50-67%. Management: The patient is immediately transferred to the cardiac intensive care unit. A norepinephrine infusion is started for vasopressor support targeting MAP >65 mmHg. The heart team is activated for emergency primary PCI. Given the refractory shock, an Impella CP device is placed for left ventricular mechanical circulatory support. The patient undergoes successful primary PCI of the left anterior descending artery with drug-eluting stent placement. Post-procedure, the patient remains on inotropic and vasopressor support with improving hemodynamics. An intra-aortic balloon pump is not used given the Impella support. The patient is monitored for mechanical complications (papillary muscle rupture, ventricular septal defect, free wall rupture) and ventricular arrhythmias.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Acute Pulmonary Edema:

🔗Related Diseases & Conditions

These conditions are clinically associated with Acute Pulmonary Edema through shared risk-scoring calculators and assessment tools:

• Acute Myocardial Infarction (STEMI)
• Cardiogenic Shock

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Confusing Killip class with NYHA functional class

  ✅ Correction: Killip class is specifically for acute MI patients and is based on physical examination findings of heart failure severity (rales, S3, JVP, BP, peripheral perfusion). NYHA class is a functional assessment for patients with chronic heart failure, based on the patient's self-reported symptom burden during physical activity (dyspnea, fatigue, palpitations). The two classifications serve different clinical purposes and patient populations and are not interchangeable.

• ❌ Mistake: Assigning Killip class based on chest X-ray or echo findings alone

  ✅ Correction: Killip class is a clinical examination-based classification, not a radiographic or echocardiographic one. While CXR can confirm pulmonary edema and echocardiography can confirm left ventricular dysfunction and assess severity, the class is assigned based on bedside physical findings. A patient with severe LV dysfunction on echo but clear lungs on auscultation and normal JVP is Killip Class I.

• ❌ Mistake: Failing to distinguish between Killip Class II and Class III based on the extent of rales

  ✅ Correction: The key distinction is whether rales cover <50% of lung fields (Class II, bibasilar rales) or >50% (Class III, extending to upper zones). This is a clinical bedside estimation. Class III represents acute pulmonary edema with severe respiratory distress, while Class II represents milder pulmonary congestion without respiratory failure.

• ❌ Mistake: Not reassessing Killip class during hospitalization

  ✅ Correction: Killip class is dynamic. A patient who presents as Class IV (cardiogenic shock) may improve to Class II after successful revascularization and diuresis. Conversely, a Class I patient who develops acute mitral regurgitation from papillary muscle rupture can rapidly deteriorate to Class IV. Serial assessments guide treatment decisions.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Acute Pulmonary Edema; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References